Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhonglin Hao

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Oncotargets and Therapy|August 1, 2015
Volasertib for AML: clinical use and patient considerationZhonglin Hao, Vamsi Kota
Oncotargets and Therapy|September 24, 2016
Sunitinib: the antiangiogenic effects and beyondZhonglin Hao, Ibrahim Sadek
Frontiers in Bioscience (Landmark Edition)|January 2, 2015
E3 ubiquitin ligase Skp2 as an attractive target in cancer therapyZhonglin Hao, Shuang Huang
The Oncologist|February 12, 2020
Lenvatinib in Management of Solid TumorsZhonglin Hao, Peng Wang
American Journal of Translational Research|October 5, 2013
A novel piperazine derivative potently induces caspase-dependent apoptosis of cancer cells via inhibition of multiple cancer signaling pathwaysEdward X She, Zhonglin Hao
Clinical Lung Cancer|October 17, 2021
Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line TherapyZhonglin Hao, Janeesh Sekkath Veedu
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 16, 2011
Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarkerZhonglin Hao, Hui Zhang, John Cowell
BMJ Case Reports|August 30, 2024
Pulmonary pleomorphic carcinoma: current understanding illustrated through a caseTsering Dolkar, Kim Absher, Zhonglin Hao
Journal for Immunotherapy of Cancer|January 6, 2025
New developments in immunotherapy for SCLCTsering Dolkar, Christopher Gates, Zhonglin Hao, et al.
BMJ Case Reports|August 30, 2013
Suppression of respiratory papillomatosis with malignant transformation by erlotinib in a kidney transplant recipientZhonglin Hao, Thomas Dillard, Paul Biddinger, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Oncotargets and Therapy|August 1, 2015
Volasertib for AML: clinical use and patient considerationZhonglin Hao, Vamsi Kota
Oncotargets and Therapy|September 24, 2016
Sunitinib: the antiangiogenic effects and beyondZhonglin Hao, Ibrahim Sadek
Frontiers in Bioscience (Landmark Edition)|January 2, 2015
E3 ubiquitin ligase Skp2 as an attractive target in cancer therapyZhonglin Hao, Shuang Huang
The Oncologist|February 12, 2020
Lenvatinib in Management of Solid TumorsZhonglin Hao, Peng Wang
American Journal of Translational Research|October 5, 2013
A novel piperazine derivative potently induces caspase-dependent apoptosis of cancer cells via inhibition of multiple cancer signaling pathwaysEdward X She, Zhonglin Hao
Clinical Lung Cancer|October 17, 2021
Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line TherapyZhonglin Hao, Janeesh Sekkath Veedu
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 16, 2011
Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarkerZhonglin Hao, Hui Zhang, John Cowell
BMJ Case Reports|August 30, 2024
Pulmonary pleomorphic carcinoma: current understanding illustrated through a caseTsering Dolkar, Kim Absher, Zhonglin Hao
Journal for Immunotherapy of Cancer|January 6, 2025
New developments in immunotherapy for SCLCTsering Dolkar, Christopher Gates, Zhonglin Hao, et al.
BMJ Case Reports|August 30, 2013
Suppression of respiratory papillomatosis with malignant transformation by erlotinib in a kidney transplant recipientZhonglin Hao, Thomas Dillard, Paul Biddinger, et al.
Pageof 5